actively monitoring the safety of vaccines
COVID-19 VACCINE VERSION
Our new COVID-19 vaccine-ready version has been developed specifically to monitor the safety of COVID-19 vaccines.
We have received hundreds of Expressions of Interest (EOI) from practices for the COVID-19 vaccine-ready version. These EOIs have been presented to our funding body AusVaxSafety and a number of practices have been selected.
Due to limited government funding, not all interested practices can be funded. We are currently exploring a user-pays model for practices unable to be funded. Please complete the Contact Form if you would like to be notified of the details of this option, as they become available.
COVID-19 Vaccine Data
Flu Vaccine Data
SmartVax is currently monitoring patients who have received the flu vaccine this year.
For the latest results on the rate of medical attendance following the flu vaccination across all age groups, visit AusVaxSafety.
SmartVax Pharmacy Trial
An Australian pilot program led by The University of Western Australia, in partnership with SmartVax, MedAdvisor and the Queensland University of Technology, will monitor the effects of vaccines administered by pharmacists.
The SmartVax team have developed a new module to better understand infant food allergies
SmartStartAllergy can be run independently or alongside SmartVax’s vaccine safety monitoring and reminder modules.
Lakeside Medical Centre
New South Wales
Parents appreciate the follow up and it is an important marketing tool for the practice. Our staff value the safety net it provides us. Thank you for allowing us to participate.